Subject	Consent Agenda – as at 25 June 2023
Agenda item	01d
Category	For Decision

Section A: Introduction

Six recommendations are being presented to the Board under the Consent Agenda for consideration. Detailed information on the items can be found in the relevant Committee papers in a dedicated folder on BoardEffect at:

https://gavi.boardeffect.co.uk/workrooms/6459/resources/230527

Section B: Actions Requested of the Board

The Gavi Alliance Board is requested to consider the following recommendations from the Gavi Alliance Governance Committee and the Gavi Alliance Audit and Finance Committee.

<u>Decision One – Board and Committee Appointments</u>

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) <u>Appoint</u> Sai Prasad as Board Member representing the vaccine industry developing countries in the seat currently held by Mahima Datla effective 1 July 2023 and until 30 June 2026
- b) <u>Reappoint</u> Beth Arthy as Board Member representing the United Kingdom on the donor constituency cluster anchored by the United Kingdom, effective 1 September 2023 and until 31 August 2024
- c) Reappoint the following to the Market-Sensitive Decisions Committee and to the Programme and Policy Committee effective immediately:
 - Beth Arthy (Board Member) until 31 December 2023
- d) **Appoint** the following to the Governance Committee effective 1 July 2023:
 - Sai Prasad (Board Member) until 31 December 2023

- e) **Appoint** the following to the Audit and Finance Committee effective 1 July 2023:
 - Deena Shiff (Board Member) until 31 December 2023
- f) Appoint the following to the Investment Committee effective 1 July 2023:
 - Sai Prasad (Board Member) until 31 December 2023
 - Teresa Ressel (Board Member) until 31 December 2023

Decision Two - Board Travel Policy

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

Approve the Board Travel Policy attached as Annex A to Doc 01d

Decision Three – Waiver to Independent Review Committee Terms of Reference

Recognising the importance of implementing the recommendations of the independent evaluation of Gavi's Independent Review Committee, which include the recommendation for a differentiated IRC review process, the Gavi Governance Committee **recommends** to the Gavi Alliance Board that it:

<u>Approve</u> waiving the requirement for an independent review, as outlined in the Independent Review Committee Terms of Reference, for up to five country applications of low risk and low value in 2023.

Decision Four – Independent Auditor Selection and Evaluation Policy

The Gavi Alliance Audit and Finance Committee <u>recommends</u> to the Gavi Alliance Board that it:

Approve the revised Independent Auditor Selection and Evaluation Policy as set out in Annex B to Doc 01d.

Decision Five – Treasury Policies

The Gavi Alliance Audit and Finance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) **Approve** the Treasury Governance Policy as set out in Annex C to Doc 01d; and
- b) **Approve** the Treasury Risk Management Policy as set out in Annex D to Doc 06b.

Decision Six – Washington DC Office Move

The Gavi Alliance Audit and Finance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) **Approve** up to US\$ 8 million in capitalised expenditure in relation to the new lease arrangement for the Gavi Washington DC office, noting the majority of this expense relates to the capitalisation of future lease payments which is consistent with the prior accounting treatment of current lease commitments; and
- b) <u>Delegate</u> to the CEO the authority to negotiate and execute the contractual arrangements necessary to relocate the Gavi Washington DC office.